The segment, known internally now as Pfizer Innovative Health, accounted for nearly half of Pfizer's total sales in 2015. Analysts at Jefferies broke out pros and cons of what is being called the “GEPxit” debate.
- Potential valuation uplift
- Stronger ownership and motivation for GEP employees
- Potential operational improvements
- Better access to R&D capital
- More freedom to challenge intellectual property related to biosimilars (a drug designed to have properties similar to one that is already been licensed).
- Avoiding disappointing investors that want the separation to occur
- Lack of a tax inversion
- Declining valuation comps
- Potential dis-synergies (which some investors believe are being underestimated by management)
- Increased stock price for comparisons against perceived valuations
Jefferies analysts see a 50/50 chance of the split happening, and adjusted their price target to $40/share, down from $42.
Pfizer shares traded at $34.62, up 1 percent.
|May 2016||Berenberg||Initiates Coverage on||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.